State Board of Administration of Florida Retirement System lowered its holdings in shares of Shockwave Medical, Inc. (NASDAQ:SWAV – Free Report) by 6.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,135 shares of the company’s stock after selling 750 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Shockwave Medical were worth $2,198,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in shares of Shockwave Medical during the first quarter valued at approximately $32,000. Global Retirement Partners LLC purchased a new position in Shockwave Medical during the first quarter valued at $34,000. Ameritas Advisory Services LLC bought a new stake in Shockwave Medical in the first quarter worth $35,000. PenderFund Capital Management Ltd. purchased a new stake in shares of Shockwave Medical in the first quarter worth $41,000. Finally, Banque Cantonale Vaudoise bought a new position in shares of Shockwave Medical during the first quarter valued at $57,000. Hedge funds and other institutional investors own 87.35% of the company’s stock.
Shockwave Medical Stock Down 0.9 %
SWAV opened at $209.31 on Wednesday. The stock has a market capitalization of $7.69 billion, a price-to-earnings ratio of 32.60, a PEG ratio of 46.55 and a beta of 0.98. The firm has a 50 day moving average price of $237.73 and a 200-day moving average price of $252.90. Shockwave Medical, Inc. has a twelve month low of $172.50 and a twelve month high of $320.54. The company has a quick ratio of 4.54, a current ratio of 5.69 and a debt-to-equity ratio of 0.04.
Analyst Ratings Changes
SWAV has been the topic of a number of analyst reports. Morgan Stanley dropped their price target on shares of Shockwave Medical from $335.00 to $313.00 and set an “overweight” rating on the stock in a research note on Thursday, August 10th. TheStreet cut shares of Shockwave Medical from a “b-” rating to a “c+” rating in a report on Thursday, August 10th. Wells Fargo & Company reduced their price target on shares of Shockwave Medical from $275.00 to $251.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 8th. Finally, Needham & Company LLC upped their price objective on Shockwave Medical from $325.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Shockwave Medical has a consensus rating of “Moderate Buy” and a consensus price target of $292.29.
Get Our Latest Stock Analysis on SWAV
Insider Buying and Selling at Shockwave Medical
In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the firm’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $291.84, for a total value of $1,167,360.00. Following the transaction, the insider now directly owns 60,678 shares of the company’s stock, valued at $17,708,267.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $291.84, for a total transaction of $1,167,360.00. Following the completion of the sale, the insider now directly owns 60,678 shares of the company’s stock, valued at $17,708,267.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Frank T. Watkins sold 3,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $219.29, for a total transaction of $657,870.00. Following the completion of the transaction, the director now owns 1,532 shares in the company, valued at $335,952.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,162 shares of company stock valued at $8,834,410. 3.40% of the stock is owned by company insiders.
About Shockwave Medical
ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.
Read More
- Five stocks we like better than Shockwave Medical
- Breakout Stocks: What They Are and How to Identify Them
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Virtual Riches: 3 Stocks Leading the VR Revolution
- What is Forex and How Does it Work?
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.
